BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24866833)

  • 1. Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells.
    Aoyama E; Watari I; Podyma-Inoue KA; Yanagishita M; Ono T
    Int J Mol Med; 2014 Aug; 34(2):475-82. PubMed ID: 24866833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
    Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
    Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
    Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
    Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
    Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
    Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.
    Preitner F; Ibberson M; Franklin I; Binnert C; Pende M; Gjinovci A; Hansotia T; Drucker DJ; Wollheim C; Burcelin R; Thorens B
    J Clin Invest; 2004 Feb; 113(4):635-45. PubMed ID: 14966573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
    Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
    Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
    Maida A; Lamont BJ; Cao X; Drucker DJ
    Diabetologia; 2011 Feb; 54(2):339-49. PubMed ID: 20972533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
    Naylor J; Suckow AT; Seth A; Baker DJ; Sermadiras I; Ravn P; Howes R; Li J; Snaith MR; Coghlan MP; Hornigold DC
    Biochem J; 2016 Sep; 473(18):2881-91. PubMed ID: 27422784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
    Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.